In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AI drug development start-up BioXcel Therapeutics nets $55.8mm in IPO

Executive Summary

BioXcel Therapeutics Inc. (artificial intelligence (AI) platform to identify neuro and immuno-oncology drugs) netted $55.8mm in its initial public offering of 5.45mm shares at $11 (the low end of its anticipated $11-13 range for 5mm shares).

Deal Industry
  • Biotechnology
  • Digital Health
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies